Effects of ezetimibe on visceral fat in the metabolic syndrome: a randomised controlled study
Authors:
- 3 October 2012
- journal article
- research article
- Published by Wiley in European Journal of Clinical Investigation
- Vol. 42 (12) , 1287-1294
Abstract
Eur J Clin Invest 2012; 42 (12): 1287–1294 Background Although visceral obesity, a key abnormality in the metabolic syndrome, is an important risk for cardiovascular diseases, reduction in visceral fat is hard to achieve despite intensive efforts directed at lifestyle modification. The present study was designed to investigate whether ezetimibe, an inhibitor of intestinal cholesterol absorption through its binding to Niemann‐Pick C1‐like 1, reduces visceral fat in patients with metabolic syndrome.Materials and Methods Seventy‐eight outpatients (63·7 ± 10·4 years old) with metabolic syndrome were enroled and randomly assigned to receive either ezetimibe (10 mg/day) or nothing for 6 months. Changes in visceral fat were assessed by computed tomography.Results Treatment with ezetimibe significantly improved lipid profiles. Visceral fat was decreased 7·2%, from 161·3 ± 58·6 cm2 to 148·4 ± 52·7 cm2 (P < 0·05), and adiponectin was increased 7·7%, from 3·61 ± 3·10 μg/mL to 3·86 ± 3·62 μg/mL (P < 0·05), after ezetimibe therapy; these beneficial effects were not observed in the control group. The increase in the adiponectin level was correlated with the reduction in visceral fat after ezetimibe treatment. Furthermore, ezetimibe reduced fasting insulin levels (P < 0·05) and improved the homoeostasis model assessment of insulin resistance (HOMA‐IR) (P < 0·05).Conclusions Ezetimibe reduces visceral fat with beneficial effects on adiponectin and insulin resistance in patients with metabolic syndrome, suggesting a new therapeutic approach in such patients.Keywords
This publication has 32 references indexed in Scilit:
- Metabolic Syndrome in the Pressioni Arteriose Monitorate E Loro Associazioni (PAMELA) StudyHypertension, 2007
- Relationship between Arterial Stiffness and the Risk of Coronary Artery Disease in Subjects with and without Metabolic SyndromeHypertension Research, 2007
- Relationship between Visceral Fat and Cardiovascular Disease Risk Factors: The Tanno and Sobetsu StudyHypertension Research, 2007
- Metabolic Syndrome and Risk of Cardiovascular Disease: A Meta-AnalysisThe American Journal of Medicine, 2006
- Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndromeJournal of Clinical Investigation, 2006
- The metabolic syndrome and adipocytokinesFEBS Letters, 2006
- Relationship between Metabolic Syndrome and Trp64Arg Polymorphism of the .BETA.3-Adrenergic Receptor Gene in a General Sample: The Shigaraki StudyHypertension Research, 2006
- Usefulness of Serum Adiponectin Level as a Diagnostic Marker of Metabolic Syndrome in Obese Japanese ChildrenHypertension Research, 2005
- Metabolic Syndrome and Cardiac Disease in Japanese Men: Applicability of the Concept of Metabolic Syndrome Defined by the National Cholesterol Education Program-Adult Treatment Panel III to Japanese Men-The Tanno and Sobetsu StudyHypertension Research, 2005
- Prevalence of the Metabolic Syndrome and Its Relation to All-Cause and Cardiovascular Mortality in Nondiabetic European Men and WomenArchives of internal medicine (1960), 2004